{"transactions":[{"id":1670713,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-25T11:02:10.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":30000,"derivative":{"exercise_price":0.5195,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-24-006396","document":"tm243935-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924006396/tm243935-2_4seq1.xml","form_type":"4"}},{"id":1670712,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-01-25T11:02:10.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 20,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date."}],"balance_after":40918,"source":{"system":"sec-edgar","filing":"0001104659-24-006396","document":"tm243935-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924006396/tm243935-2_4seq1.xml","form_type":"4"}},{"id":1717561,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A Common Stock","published_at":"2023-12-08T21:10:31.000Z","date":"2023-12-06","kind":"other","planned":false,"acquired":false,"shares":1082,"price":1.08,"value":1168.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction relates to shares of common stock withheld by SELLAS Life Sciences Group, Inc. (the \"Issuer\") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs."}],"balance_after":20918,"source":{"system":"sec-edgar","filing":"0001104659-23-124687","document":"tm2332459-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923124687/tm2332459-2_4seq1.xml","form_type":"4"}},{"id":2032345,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T22:14:54.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-quarter (1/4) of the option shares will vest and became exercisable one year from the February 2, 2023 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":45000,"derivative":{"exercise_price":3.34,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-23-010637","document":"tm235353d6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923010637/tm235353d6_4seq1.xml","form_type":"4"}},{"id":2032344,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-03T22:14:54.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 12,000 restricted stock units on February 2, 2023, which shall vest as follows: (i) 25% on December 1, 2023 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001104659-23-010637","document":"tm235353d6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923010637/tm235353d6_4seq1.xml","form_type":"4"}},{"id":2332854,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-15T20:05:52.000Z","date":"2022-03-14","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 14, 2022 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter."}],"balance_after":100000,"derivative":{"exercise_price":5.23,"expiration_date":"2032-03-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-22-033927","document":"tm229354-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465922033927/tm229354-1_4seq1.xml","form_type":"4"}},{"id":3114501,"issuer":{"id":148550,"kind":"organization","name":"STEMLINE THERAPEUTICS INC","symbol":"STML"},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-06-10T11:17:18.000Z","date":"2020-06-10","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All options were vested and exercisable as of the effective time of the merger."}],"balance_after":0,"derivative":{"exercise_price":9.79,"expiration_date":"2026-09-19","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-20-071832","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264587/000110465920071832/a4.xml","form_type":"4"}},{"id":3114500,"issuer":{"id":148550,"kind":"organization","name":"STEMLINE THERAPEUTICS INC","symbol":"STML"},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-06-10T11:17:18.000Z","date":"2020-06-10","kind":"other","acquired":false,"shares":200891,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the \"Merger Agreement\"), in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right (\"CVR\") per share (collectively, the \"Offer Price\").  Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-071832","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264587/000110465920071832/a4.xml","form_type":"4"}},{"id":3159297,"issuer":{"id":148550,"kind":"organization","name":"STEMLINE THERAPEUTICS INC","symbol":"STML"},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-05-06T21:31:41.000Z","date":"2020-05-04","kind":"sale","acquired":false,"shares":272,"price":11.51,"value":3130.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the vesting of 1,878 shares on May 2, 2020 a total of 272 shares were sold by the Company on May 4, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the weighted average sale price. The range of prices for the shares sold on May 4, 2020 was $11.81 to $12.02. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares listed, 144,425 shares are restricted stock."}],"balance_after":197658,"source":{"system":"sec-edgar","filing":"0001104659-20-057631","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264587/000110465920057631/a4.xml","form_type":"4"}},{"id":3210736,"issuer":{"id":148550,"kind":"organization","name":"STEMLINE THERAPEUTICS INC","symbol":"STML"},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-13T21:31:50.000Z","date":"2020-03-09","kind":"sale","acquired":false,"shares":1266,"price":5,"value":6330.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the vesting of 3,253 shares on March 8, 2020 a total of 1,266 shares were sold by the Company on March 9, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the weighted average sale price. The range of prices for the shares sold on March 9, 2020 was $5.00 to $5.02. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares listed, 146,303 shares are restricted stock."}],"balance_after":197930,"source":{"system":"sec-edgar","filing":"0001104659-20-033490","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264587/000110465920033490/a4.xml","form_type":"4"}},{"id":3270253,"issuer":{"id":148550,"kind":"organization","name":"STEMLINE THERAPEUTICS INC","symbol":"STML"},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-02-14T21:29:07.000Z","date":"2020-02-10","kind":"grant","acquired":true,"shares":105939,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The 105,939 restricted shares will vest in three installments as follows: 35,313 shares on February 24, 2021; 35,313 shares on April 6, 2022; and 35,313 shares on January 25, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Of the shares listed, 149,556 shares are restricted stock."}],"balance_after":199196,"source":{"system":"sec-edgar","filing":"0001104659-20-022139","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264587/000110465920022139/a4.xml","form_type":"4"}},{"id":3270252,"issuer":{"id":148550,"kind":"organization","name":"STEMLINE THERAPEUTICS INC","symbol":"STML"},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-02-14T21:29:07.000Z","date":"2020-02-07","kind":"sale","acquired":false,"shares":5064,"price":6.72,"value":34030.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the vesting of 12,388 shares on February 6, 2020 a total of 5,064 shares were sold by the Company on February 7, 2020 in order to satisfy the reporting person's tax witholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the weighted average sale price. The range of prices for the shares sold was $6.66 to $6.81. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares listed, 43,617 shares are restricted stock."}],"balance_after":93257,"source":{"system":"sec-edgar","filing":"0001104659-20-022139","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264587/000110465920022139/a4.xml","form_type":"4"}},{"id":3322295,"issuer":{"id":148550,"kind":"organization","name":"STEMLINE THERAPEUTICS INC","symbol":"STML"},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-01-03T17:17:32.000Z","date":"2019-12-27","kind":"sale","acquired":false,"shares":116,"price":10.48,"value":1215.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the vesting of 5,327 shares on December 21, 2019, a total of 2,670 shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.  249 shares were sold on December 23, 2019; 1,412 shares were sold on December 24, 2019; 893 shares were sold on December 26, 2019; and 116 shares were sold on December 27, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76.  The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares listed, 56,005 shares are restricted stock."}],"balance_after":98321,"source":{"system":"sec-edgar","filing":"0001104659-20-000976","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264587/000110465920000976/a4.xml","form_type":"4"}},{"id":3322294,"issuer":{"id":148550,"kind":"organization","name":"STEMLINE THERAPEUTICS INC","symbol":"STML"},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-01-03T17:17:32.000Z","date":"2019-12-26","kind":"sale","acquired":false,"shares":893,"price":10.75,"value":9599.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the vesting of 5,327 shares on December 21, 2019, a total of 2,670 shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.  249 shares were sold on December 23, 2019; 1,412 shares were sold on December 24, 2019; 893 shares were sold on December 26, 2019; and 116 shares were sold on December 27, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76.  The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares listed, 56,005 shares are restricted stock."}],"balance_after":98437,"source":{"system":"sec-edgar","filing":"0001104659-20-000976","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264587/000110465920000976/a4.xml","form_type":"4"}},{"id":3322293,"issuer":{"id":148550,"kind":"organization","name":"STEMLINE THERAPEUTICS INC","symbol":"STML"},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-01-03T17:17:32.000Z","date":"2019-12-24","kind":"sale","acquired":false,"shares":1412,"price":10.97,"value":15489.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the vesting of 5,327 shares on December 21, 2019, a total of 2,670 shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.  249 shares were sold on December 23, 2019; 1,412 shares were sold on December 24, 2019; 893 shares were sold on December 26, 2019; and 116 shares were sold on December 27, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76.  The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares listed, 56,005 shares are restricted stock."}],"balance_after":99330,"source":{"system":"sec-edgar","filing":"0001104659-20-000976","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264587/000110465920000976/a4.xml","form_type":"4"}},{"id":3322292,"issuer":{"id":148550,"kind":"organization","name":"STEMLINE THERAPEUTICS INC","symbol":"STML"},"owners":[{"id":94897,"kind":"person","name":"Francomano Robert","position":1,"cik":"0001797467","reported_name":"Francomano Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-01-03T17:17:32.000Z","date":"2019-12-23","kind":"sale","acquired":false,"shares":249,"price":10.58,"value":2634.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the vesting of 5,327 shares on December 21, 2019, a total of 2,670 shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.  249 shares were sold on December 23, 2019; 1,412 shares were sold on December 24, 2019; 893 shares were sold on December 26, 2019; and 116 shares were sold on December 27, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76.  The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares listed, 56,005 shares are restricted stock."}],"balance_after":100742,"source":{"system":"sec-edgar","filing":"0001104659-20-000976","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264587/000110465920000976/a4.xml","form_type":"4"}}]}